AlphAIAlphAI — Financial news for AI agents
investing.comOCT 282 min read$BIIB

Biogen earnings beat by $0.60, revenue topped estimates

Biogen (BIIB) reported Q3 EPS of $2.62, beating estimates by $0.60, with revenue at $2.8B, topping expectations. The company provided FY 2026 EPS guidance of $12.20-$13.00, below the consensus. BIIB's stock is up 24.53% in 3 months and 70.93% in 12 months.

Original reporting
investing.com
Published Oct 28, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BIIB
Bullish
high confidence
Mentioned
$BIIB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BIIBBullishHigh
01

Why it matters

The earnings surprise may trigger buying interest and lift the stock in after-hours trading.

02

Market read

Earnings beat and raised guidance are material for traders focusing on biotech equities.

03

What to watch

Potential upcoming patent expirations or pipeline setbacks not mentioned.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Biogen (NASDAQ: BIIB) released its third-quarter earnings, surpassing analyst estimates and providing an optimistic FY 2026 outlook.

Company-level read

Ticker impact

$BIIBBullishHigh confidence
Context

Biogen reported Q3 EPS of $2.62 beating estimates by $0.60 and raised FY 2026 EPS guidance to $12.20-$13.00.

Expected impact

likely upward as the market prices in the earnings beat and higher guidance

Evidence & confidence

The beat exceeds consensus by a sizable margin and guidance is above expectations, which typically drives buying.

Market effects

Sector

Biotech sector may see broader optimism as a major player beats expectations.

Regional

U.S. biotech stocks could rally in after-hours trading.

Global

Limited to investors tracking U.S. pharma/biotech equities.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short-term profit taking.

Key entities

  • Company
    Biogen

    Biotech firm reporting earnings.

Read at source← All news

StoryBiogen posts Q3 earnings beat and lifts FY2026 non‑GAAP EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$BIIBHighAI 8/10

Biogen Slips To Loss In Q3; Raises Low-end Of FY26 Earnings View

Biogen (BIIB) reported a Q3 loss of $20.6M, down from a $466.5M profit last year, despite an 11% revenue increase to $2.8B. Adjusted EPS was $2.62, down from $4.81. The loss was driven by transaction-related charges. Biogen raised its low-end FY26 EPS outlook to $12.20-$13.00, up from $12.00-$13.00. Shares were down 0.29% in premarket trading.

rttnews.com2 min
OCT 28
$BIIBHighAI 9/10

Biogen boosts outlook after Q3 beat on multiple sclerosis franchise

Biogen (BIIB) reported Q3 2026 revenue of $2.8B, beating estimates by $170M. MS product revenue reached $919M, exceeding projections. Spinraza outperformed with $461M in sales. Syfovre and Empaveli, from the Apellis acquisition, contributed $191M and $52M respectively. Leqembi sales were $202M, slightly below consensus. Non-GAAP EPS fell 46% YoY to $2.62, but beat estimates. Biogen raised its full-year earnings outlook.

tradingview.com4 min
OCT 28
$BIIBHighAI 9/10

Biogen beats Q3 estimates, raises guidance floor on growth

Biogen Inc reported Q3 adjusted EPS of $2.62, beating estimates by $0.60, with revenue of $2.8B, up 11% YoY. Growth Portfolio revenue rose 49% YoY. The company raised its 2026 adjusted EPS guidance floor to $12.20-$13.00. Key products like SPINRAZA, LEQEMBI, and SYFOVRE showed strong sales growth. Biogen expects mid-single digit revenue growth for 2026.

finance.yahoo.com5 min
OCT 28
$BIIBHighAI 8/10

Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance

Biogen reported Q3 2026 revenue of $2.8B, up 11% YoY, with non-GAAP EPS of $2.62. GAAP net loss was $20.6M due to transaction-related charges. The company raised its full-year non-GAAP EPS guidance to $12.20–$13.00. Growth was driven by its acquired Apellis products and strong performance from SPINRAZA, LEQEMBI, and SYFOVRE.

tradingview.com1 min